Inventiva (IVA) Non-Current Debt (2018 - 2025)
Inventiva (IVA) recorded quarterly Non-Current Debt of $58.4 billion in Q2 2025, up 12.79% quarter-over-quarter from $51.8 billion in Q4 2024, and up 115678.89% on a YoY basis from N/an in Q2 2024.
Inventiva (IVA) Non-Current Debt (2018 - 2025) Analysis & Trends
Inventiva's Non-Current Debt history runs 8 years deep, the most recent figure standing at $58.4 billion for Q2 2025.
- In Q2 2025, Non-Current Debt rose 115678.89% year-over-year to $58.4 billion; the TTM figure through Jun 2025 stood at $58.4 billion (up 115678.89% YoY), while the FY2024 annual figure was $51.8 billion, changed N/A from the prior year.
- Non-Current Debt was $58.4 billion for Q2 2025 at Inventiva, up from $51.8 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $58.4 billion in Q2 2025 to a low of $10.1 million in Q4 2021.
- Historically, Non-Current Debt has averaged $13.9 billion across 5 years, with a median of $33.8 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt jumped 118026.67% in 2022, then slumped 99.76% in 2023.
- A 5-year view of Non-Current Debt shows it stood at $10.1 million in 2021, then soared by 189.27% to $29.2 million in 2022, then advanced by 15.49% to $33.8 million in 2023, then jumped by 153234.97% to $51.8 billion in 2024, then climbed by 12.79% to $58.4 billion in 2025.
- The last three Non-Current Debt figures came in at $58.4 billion (Q2 2025), $51.8 billion (Q4 2024), and $50.4 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Inventiva | 8.93 Mn | -259.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 58.41 Bn |
| Jun 30, 2025 | 58.41 Bn |
| Dec 31, 2024 | 51.78 Bn |
| Dec 31, 2024 | 51.78 Bn |
| Jun 30, 2024 | 50.45 Mn |
| Jun 30, 2024 | 50.45 Mn |
| Jun 30, 2023 | 33.77 Mn |
| Jun 30, 2023 | 33.77 Mn |
| Dec 31, 2022 | 29.24 Mn |
| Dec 31, 2022 | 29.24 Mn |
| Jun 30, 2022 | 14.34 Bn |
| Jun 30, 2022 | 14.34 Bn |
| Dec 31, 2021 | 10.11 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Jun 30, 2021 | 12.14 Mn |
| Jun 30, 2021 | 12.14 Mn |
| Mar 31, 2021 | 12.15 Mn |
| Mar 31, 2021 | 12.15 Mn |
| Dec 31, 2020 | 11.97 Mn |
| Dec 31, 2020 | 11.97 Mn |